Bausch + Lomb receives permanent J-Code for triamcinolone acetonide injectable suspension
Ophthalmology Times,
Bausch + Lomb Corp. today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has issued a permanent…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
SNN,
SOURCE Bausch + Lomb Corporation Survey Reinforces Need for Innovative Therapies, Including Options Administered Through…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Ticker Tech,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Spoke,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WMBF News,
Published: May. 12, 2022 at 6:59 AM EDT|Updated: 13 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WDAM - TV,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
KPLC 7 News,
Published: May. 12, 2022 at 5:59 AM CDT|Updated: 15 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WALB,
Published: May. 12, 2022 at 6:59 AM EDT|Updated: 11 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WFLX Fox 29,
Published: May. 12, 2022 at 6:59 AM EDT|Updated: 13 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
News story from WHSV3 on Thursday 12 May 2022
WHSV3,
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
14 News,
Published: May. 12, 2022 at 5:59 AM CDT|Updated: 12 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WFMZ-TV 69,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
News Channel 10,
Published: May. 12, 2022 at 5:59 AM CDT|Updated: 11 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WBTV,
Published: May. 12, 2022 at 6:59 AM EDT|Updated: 11 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Fox 19,
Published: May. 12, 2022 at 6:59 AM EDT|Updated: 11 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WILX 10,
/PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
KCBD,
Published: May. 12, 2022 at 5:59 AM CDT|Updated: 10 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WWSB,
Published: May. 12, 2022 at 6:59 AM EDT|Updated: 10 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Yahoo! Finance USA,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
KLTV,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WECT News 6,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Knoe News 8,
Published: May. 12, 2022 at 5:59 AM CDT|Updated: 9 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
KAIT-TV,
Published: May. 12, 2022 at 5:59 AM CDT|Updated: 7 minutes ago VAUGHAN, ON, May 12, 2022 /PRNewswire/ -- Bausch + Lomb…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
KEYC News 12,
Published: May. 12, 2022 at 5:59 AM CDT|Updated: 7 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
News story from wrdw on Thursday 12 May 2022
wrdw,
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Fox 8 WVUE,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
NBC12,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Morning Star,
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
South Carolina News Now,
Published: May. 12, 2022 at 6:59 AM EDT|Updated: 8 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Hawaii News Now,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WTVM,
/PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WCAX,
Published: May. 12, 2022 at 6:59 AM EDT|Updated: 6 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Wave 3 News,
Published: May. 12, 2022 at 6:59 AM EDT|Updated: 7 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
KSLA News 12,
Published: May. 12, 2022 at 5:59 AM CDT|Updated: 6 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WAFB 9,
Published: May. 12, 2022 at 5:59 AM CDT|Updated: 6 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
PR Newswire,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
WSAW-TV,
Published: May. 12, 2022 at 5:59 AM CDT|Updated: 5 minutes ago Survey Reinforces Need for Innovative Therapies, Including…
New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis
Biospace,
Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space VAUGHAN, ON, May 12…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Spoke,
LAVAL, QC and ALPHARETTA, Ga., March 28, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Ticker Tech,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
ProfitQuotes.com,
LAVAL, QC and ALPHARETTA, Ga., March 28, 2022 -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
WWSB,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
KCBD,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
WFMZ-TV 69,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
NBC12,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Yahoo! Finance USA,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
KPLC 7 News,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Fox 19,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
News Channel 10,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Wave 3 News,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
WTVM,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Hawaii News Now,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Morning Star,
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
WALB,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Biospace,
XIPERE® is the First and Only FDA-Approved Therapy for Delivery via Suprachoroidal Injection LAVAL, QC and ALPHARETTA, Ga.…
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
FirstWord Pharma,
XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method…
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Spoke,
LAVAL, QC and ALPHARETTA, Ga., Oct. 25, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch…
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Crwe World,
XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method…
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Yahoo! Finance USA,
XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method…
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
PR Newswire,
XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method…
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
WFMZ-TV 69,
XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method…
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Morning Star,
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for…
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Biospace,
XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method…